Comparison Between Metformin and Glyburide in the Management of Gestational Diabetes
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorAssiut University
About this trial
This study aims to compare the maternal, fetal, and neonatal outcomes associated with the use of metformin versus glyburide for managing gestational diabetes.
The objective is to assess the safety and effectiveness profiles of both medications as potential alternatives to initiating insulin therapy.
Eligibility criteria
Qualifiers
Pregnant women over 18 years old.
Gestational age between 24 - 28 weeks.
New diagnosis of gestational diabetes mellitus using a 2-hour glucose tolerance test.
Medical therapy is indicated to control blood glucose following the failure of diet and lifestyle changes to solely achieve glycemic control (A2GDM).
Disqualifiers
First trimester fasting blood glucose ≥105 mg/dl or HbA1c > 6.4%.
Major fetal anomalies.
Intrauterine growth restriction (IUGR) before 24 weeks.
Abnormal renal or liver function.
Trial design
Treatments tested in this trial
- MetFORMIN 500 Mg Oral Tablet
- GlyBURIDE 2.5 MG Oral Tablet
Treatment groups
180 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Assiut University
Lead sponsor
Middle-Eastern College of Obstetricians and Gynecologists
Sponsor institution
Middle-Eastern College of Obstetricians and Gynecologists
Collaborator
Source ClinicalTrials.gov